

The **CRISPR** Revolution: From Reading to Editing Genomes

One Health Research Symposium Kansas City August 19, 2018

Kevin Davies PhD

Executive Editor, The CRISPR Journal






C R I S P R



No hunger. No pollution. No disease. And the end of life as we know it. DISRUPTING PRIONS Small molecules target progressive diseases P.37 **BOSTON IN PHOTOS** Sights from the fall 2015 S national meeting P48 EMICAL & ENGINEERING NEWS EDITING THE GENOME CRISPR/Cas9 takes gene manipulation into a new era P.14






CRISPR in the Public Eye

A CRACK IN CREATION

GENE EDITING AND THE UNTHINK BLE POWER TO CONTROL EVOLUTION

JENNIFER A. DOUDNA Samuel H. Sternberg



OCTOBER 18, 2016 Z:31pm PT by Lesley Goldberg

MOVIES TY BUSINESS STYLE POLITICS TECH CULTURE AWARDS VIDEO

Jennifer Lopez Sets Futuristic Bio-Terror Drama at NBC (Exclusive)



Amanda Edwards/Wirelma Jennifer Lopez

'C.R.I.S.P.R.' — aka "clustered regularly interspaced short palindromic repeats" — marks her latest project for the network.



Newsletters

a

NBC is reteaming with Jennifer Lopez for a futuristic procedural.

BIG MEETS BIGGE<u>R</u>

"Are you familiar with CRISPR?"



LEGAL FILM RATING PARENTAL GUIDE MPAA AD CHOICES PRIVACY TERMS

© 2018 WARNER BROS. ENT. ALL RIGHTS RESERVED.

tes nenats



We've gone from reading DNA...



National Human Genome Research Institute

April 14, 2003

Newsroom

<u>News Releases</u> + International Consortium Completes Human Genome Project



National Human Genome Research Institute National Instututes of Health Department of Health and Human Services and Office of Science U.S. Department of Energy

International Consortium Completes Human Genome Project

All Goals Achieved; New Vision for Genome Research Unveiled

oc THESDA, Md., April 14, 2003 - The International Human Genome Sequencing Consortium, led in the United States by the National Human Genome Research Institute (NHGRI) and the Department of Energy (DOE), today announced the successful completion of the Human Genome Project more than two years ahead of schedule.

Also today, NHGRI unveiled its bold new vision for the future of genome research, officially ushering in the era of the genome. The vision will be published in the April 24 issue of the journal *Nature*, coinciding with the 50th anniversary of *Nature's* publication of the landmark paper by Nobel Laureates James Watson and Francis Crick that described DNA's double helix. Dr. Watson also was the first leader of the <u>Human Genome Project</u>

The international effort to sequence the 3 billion DNA letters in the human genome is considered by many to be one of the most ambitious scientific undertakings of all time, even compared to splitting the atom or going to the moon.

"The Human Genome Project has been an amazing adventure into ourselves, to understand our own DNA instruction book, the shared inheritance of all humankind," said NHGRI Director Francis S. Collins, M.D., Ph.D., leader of the Human Genome Project since 1993. "All of the project's goals have been completed successfully - well in advance of the original deadline and for a cost substantially less than the original estimates."

like My


19 March 1953

Jim Watson and I have probably made a most important discovery...

Our structure is very beautiful. D.N.A. can be thought of roughly as a very long chain with flat bits sticking out. The flat bits are called the 'bases'...

... Lots of love, Daddy"










Sir Shankar Balasubramanian & David Klenerman The Panton Arms / University of Cambridge, UK



Houston 31 May 2007



... to writing DNA...



CENTER of EXCELLENCE for ENGINEERING BIOLOGY



All the he he had the the the the start and the


CP-WRITE ABOUT FAQ CONSORTIUM PILOT PROJECTS WORKING GROUPS RESOURCES EVENTS MEDIA BLOG CONTACT




A Grand Challenge

The Genome Project-write (GP-write) is an open, international research project led by a multi-disciplinary group of scientific leaders who will oversee a reduction in the costs of engineering and testing large genomes in cell lines more than 1,000-fold within ten years.


Download the GPwrite White Paper



Shao et al., Luo et al. Nature July 2018



CRISPR: <u>C</u>lustered <u>R</u>egularly Interspaced <u>Short Palindromic</u>



TGATTTTATATCCTGCTTACCGAGGGTTAAAAAAAAACATCATTTTT ACCCTTTGGCGAAAGAATTATTTTACAAACAGTCTGTTACCCGT ATTATCTTACTGTTCACTGCCGCACAGGCAGCTTAGAAACCTGA TACAATCATCCTATTTGTCCTATCCAGAAGTTCACTGCCGCACAG GCAGCTTAGAAAGACAAGAACCGAATCTTTCGCCGTGCCGTAAA GTTCACTGCCGCACAGGCAGCTTAGAAACCGAAATCATCAGATG TAATTAAGATTTTTGCTGTTCACTGCCGCACAGGCAGCTTAGAA AAGACTGATGCAAGATGGCGGTATGCGTACAGAGTTCACTGCCG CACAGGCAGCTTATAGA Francisco Mojica Salt Lakes of Santa Pola



Asunto: Re: Acronym

Fecha: Wed, 21 Nov 2001 16:39:06 +0100 De: "Ruud Jansen" <R.Jansen@vet.uu.nl> Empresa: Diergeneeskunde

A: "Francisco J. Martínez Mojica" <fmojica@ua.es>

Dear Francis

What a great acronym is CRISPR. I feel that every letter that was removed in the alternatives made it less crispy so I prefer the snappy CRISPR over SRSR and SPIDR. Also not unimportant is the fact that in MedLine CRISPR is a unique entry, which is not true for some of the other shorter acronyms.

> **Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements**


© Springer Science+Business Media, Inc. 2005


Francisco J.M. Mojica, César Díez-Villaseñor, Jesús García-Martínez, Elena Soria

División de Microbiología, Departamento de Fisiología, Genética y Microbiología, Universidad de Alicante, Campus de San Vicente, E-03080, Spain

Received: 6 February 2004 / Accepted: 1 October 2004 [Reviewing Editor: Dr. John Huelsenbeck]

CRISPR is a naturally occurring, bacterial immune defense system that provides a means to recognize, remember and destroy viral invaders





Heroes of CRISPR





Koonin

Barrangou



Makarova

Chylinski



Fremaux



Marraffini Sontheimer

Gasiunas

Siksnys



Garneau





Jinek



Mali








Zhang











A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Martin Jinek,^{1,2}* Krzysztof Chylinski,^{3,4}* Ines Fonfara,⁴ Michael Hauer,²† Jennifer A. Doudna,^{1,2,5,6}‡ Emmanuelle Charpentier⁴‡

JAPAN


Clustered regularly interspaced short palindromic repeats (CRISPR//CRISPR-associated (Cas) syst provide bacteria and archaea with adaptive immunity against viruses and plasmids by using CRISPR RNAs (crRNAs) to guide the silencing of invading nucleic acids. We show here that in

Emmanuelle Charpentier

PRIZE

JAPAN PRIZE

Jennifer Doudna



Feng Zhang (MIT/Broad Institute)

Multiplex Genome Engineering Using CRISPR/Cas Systems

Le Cong,^{1,2*} F. Ann Ran,^{1,4*} David Cox,^{1,3} Shuailiang Lin,^{2,5} Robert Barretto,⁶ Naomi Habib,¹ Patrick D. Hsu,^{1,4} Xuebing Wu,⁷ Wenyan Jiang,⁸ Luciano A. Marraffini,⁸ Feng Zhang¹†

Functional elucidation of causal genetic variants and elements requires precise genome editing technologies. The type II prokaryotic CRISPR (clustered regularly interspaced short palindromic repeats)/Cas adaptive immune system has been shown to facilitate RNA-guided site-specific DNA cleavage. We engineered two different type II CRISPR/Cas systems and demonstrate that Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in human and mouse cells. Cas9 can also be converted into a nicking enzyme to facilitate homology-directed repair with minimal mutagenic activity. Lastly, multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several sites within the mammalian genome, demonstrating easy programmability and wide applicability of the RNA-guided nuclease technology.

Precise and efficient genome-targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements. Although genome-editing technologies such as designer zinc fingers (ZFs) (1-4), transcription activator-like effectors (TALEs) (4-10), and homing meganucleases (11) have be-


gun to enable targeted genome modifications, there remains a need for new technologies that are scalable, affordable, and easy to engineer. Here, we report the development of a class of precision genomeengineering tools based on the RNA-guided Cas9 nuclease (12–14) from the type II prokaryotic clustered regularly interspaced short palindromic repeats (CRISPR) adaptive immune system (15–18).

www.sciencemag.org SCIENCE VOL 339 15 FEBRL

Lights. Camera. Action... CUT!

CRISPR-Cas9 visualized by high-speed atomic force microscopy

M. Shibata, H. Nishmasu *et al*. *Nature Communications* 8, 1430 (2017)




Hiroshi Nishimasu (Univ Tokyo)

The Heroes of CRISPR

Eric S. Lander^{1,2,3,*}


¹Broad Institute of MIT and Harvard, 415 Main Street, Cambridge, I ²Department of Biology, Massachusetts Institute of Technology, Ca ³Department of Systems Biology, Harvard Medical School, Boston, *Correspondence: lander@broadinstitute.org http://dx.doi.org/10.1016/j.cell.2015.12.041

Three years ago, scientists reported that CRIS genome editing in living eukaryotic cells. Since the by storm, with thousands of labs using it for app preceding 20-year journey—the discovery of a start as an adaptive immune system; its biological ch gineering—remains little known. This Perspective and the stories of pioneers—and draw lessons a tific discovery.



Lander's essay "is his masterwork, at once so evil and yet so brilliant that I find it hard not to stand in awe even as I picture him cackling loudly in his Kendall Square lair, giant laser weapon behind him poised to destroy Berkeley if we don't hand over our patents." --- Michael Eisen (HHMI/UC Berkeley)


CRISPR Business






(Charpentier)






CRISPR Gene Therapy



The Scientist

Genome Editing B.C. (Before CRISPR)



van der Oost J. *Science* Feb 2013

"Invisible Mending"

Home » Latest News » National News » AP Exclusive: US scientists...

AP Exclusive: US scientists try 1st gene editing in the body



Brian Madeux, 44, uses an infrared device to look at his veins as nurse Siobhan Field prepares an IV line for the first human gene editing therapy for NPS, at the UCSF Benioff Children's Hospital Oakland in Oakland, Calif., on Monday, Nov. 6, 2017. Madeux, who...

OAKLAND, Calif. (AP) — Scientists for the first time have tried editing a gene inside the body in a bold attempt to permanently change a person's DNA to try to cure a disease. It's kind of humbling. I'm willing to take that risk.
Hopefully it will help me and other people."

--- Brian Madeux, 44 Hunter Syndrome patient

Associated Press, Nov 15, 2017

New hope for China's left-behind kids p. 1226

How pesticides should be regulated *p. 1232*

A twist on photoemiss delay pp. 1239 & 1274

Science States and Sta

Eliminating endogenous retrovirus in a step toward xenotransplantation

REPORT


Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9

Luhan Yang (eGenesis)

Dong Niu^{1,2,*}, Hong-Jiang Wei^{3,4,*}, Lin Lin^{5,*}, Haydy George^{1,*}, Tao Wang^{1,*}, I-Hsiu Lee^{1,*}, Hong-Ye Zhao³, Yong Wang⁶, Yinan Kan¹, Ellen Shrock⁷, Emal Lesha¹, Gang Wang¹, Yonglun Luo⁵, Yubo Qing^{3,4}, Deling Jiao^{3,4}, Heng Zhao^{3,4}, Xiaoyang Zhou⁶, Shouqi Wang⁸, Hong Wei⁶, Marc Güell^{1,†}, George M. Church^{1,7,9,†}, Luhan Yang^{1,†,‡}

¹eGenesis, Inc., Cambridge, MA 02139, USA.

CRISPR 2.0: Base Editing



Nicole M. Gaudelli^{1,2,3}, Alexis C. Komor^{1,2,3}, Holly A. Rees^{1,2,3}, Michael S. Packer^{1,2,3}, Ahmed H. Badran^{1,2,3}, David I. David R. Liu^{1,2,3}

Is CRISPR Safe?





Confirmatory Results


No unexpected CRISPR-Cas9 off-target activity gene-edited mice

Vivek Iyer, Katharina Boroviak, Mark Thomas, Brendan Doe, Edw **doi:** https://doi.org/10.1101/263129

This article is a preprint and has not been peer-reviewed [what does this

Abstract

CRISPR-Cas technologies have transformed genome-editing of experimental organisms and have immense therapeutic potential. Despite significant advances in our understanding of the CRISPR-Cas9 system, concerns remain over the potential for offtarget effects. Recent studies have addressed these concerns using whole-genome sequencing (WGS) of gene-edited embryos or animals to search for de novo mutations (DNMs), which may represent candidate changes induced by poor editing fidelity. Critically, these studies used strain-matched but not pedigree-matched controls and thus were unable to reliably distinguish generational or colony-related differences from true DNMs. Here we used a trio design and whole genome sequenced 8 parents and 19 embryos, where 10 of the embryos were mutagenised with well-characterised gRNAs targeting the coat colour Tyrosinase (Tyr) locus. Detailed analyses of these whole genome data allowed us to conclude that if CRISPR mutagenesis were causing SNV or indel off-target mutations in treated embryos, then the number of these mutations is not statistically distinguishable from the background rate of DNMs occurring due to other processes.



nature biotechnology

Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements

Michael Kosicki, Kärt Tomberg & Allan Bradley



"This is the first systematic assessment of unexpected events resulting from CRISPR/Cas9 editing in therapeutically relevant cells, and we found that changes in the DNA have been seriously underestimated before now. It is important that anyone thinking of using this technology for gene therapy proceeds with caution, and looks very carefully to check for possible harmful effects."

Allan Bradley Director Emeritus Wellcome Sanger Institute

ARTICLE

doi:10.1038/nature23305

Correction of a pathogenic gene mutation in human embryos


Hong Ma¹*, Nuria Marti-Gutierrez¹*, Sang-Wook Park²*, Jun Wu³*, Yeonmi Lee¹, Keiichiro Suzuki³, Amy Koski¹, Dongmei Ji¹, Tomonari Hayama¹, Riffat Ahmed¹, Hayley Darby¹, Crystal Van Dyken¹, Ying Li¹, Eunju Kang¹, A.-Reum Park², Daesik Kim⁴, Sang-Tae Kim², Jianhui Gong^{5,6,7,8}, Ying Gu^{5,6,7}, Xun Xu^{5,6,7}, David Battaglia^{1,9}, Sacha A. Krieg⁹, David M. Lee⁹, Diana H. Wu⁹, Don P. Wolf¹, Stephen B. Heitner¹⁰, Juan Carlos Izpisua Belmonte³§, Paula Amato^{1,9}§, Jin-Soo Kim^{2,4}§, Sanjiv Kaul¹⁰§ & Shoukhrat Mitalipov^{1,10}§


Genome edit the heterozy accuracy and response. In homologous the DSB was embryos cari safety of the : embryos by c applications,





The concept of altering the human germline in embryos for clinical purposes has been debated over many years from many different perspectives, and has been viewed almost universally as a line that should not be crossed... Designer babies make great Hollywood movies. They make really bad science, and I think they are really bad ethics."





Gene editing is already used to make GM-persons [cancer, HIV]... If by GM-persons, we limit our meaning to heritable DNA changes, then the most likely use would be changing deadly DNA variants into their common healthy versions. This should be far safer than testing new drugs, which impact complex human systems in unknown ways."

NEWS RELEASES

Tuesday, January 23, 2018

NIH to launch genome editing research program

Somatic Cell Genome Editing aims to develop tools for safe and effective genome editing in humans.

🗟 🖬 🕇 💆 G+

The National Institutes of Health will launch an effort aimed at removing barriers that slow the adoption of genome editing for treating patients. This program, Somatic Cell Genome Editing, plans to award researchers approximately \$190 million over six years beginning this year, pending availability of funds. These researchers will collaborate to improve the delivery mechanisms for targeting gene editing tools in patients, develop new and improved genome editors, develop assays for testing the safety and efficacy of the genome editing tools in animal and human cells, and assemble a genome editing toolkit containing the resulting knowledge, methods, and tools to be shared with the scientific community. The program is funded by NIH's Common Fund.

The National Academies of SCIENCES • ENGINEERING • MEDICINE

REPORT

Human Genome Editing Science, Ethics, AND GOVERNANCE

> NATIONAL ACADEMY OF SCIENCES NATIONAL ACADEMY OF MEDICINE


••We say proceed with all due caution, but we don't prohibit germline, after considerable discussion and debate. We're talking only about fixing diseases."

-- Rick Hynes (HHMI/MIT)

Genetically modified babies given go ahead by UK ethics body

The Nuffield Council on Bioethics says changing the DNA of a human embryo could be 'morally permissible' if it is in the child's best interests





CRISPR Goes to Washington



What Is a Genetically Modified Crop? A European Ruling Sows Confusion

In Europe, plants created with gene-editing technologies will be stringently regulated as G.M.O.'s. But older crops whose DNA has been altered will be left alone.



Corteva

Matt Ridley 🥝 Follo Omattwridley Catastrophic decision of the ECJ to go

against the advice of its advocate general and treat gene-edited crops as GMOs.

Will ensure European farming is less competitive, less innovative, more dependent on chemicals and worse for the environment.

So placing CRISPR in the same bucket of all GMO and uv, gamma, chemical mutations in another bucket is like the Catholic Church classifying ducks as fish

Jonathan Pettitt @genotripe

Ewan Birney

Clive G. Brown @Clive_G_Brown

Mark Lynas 📀

@mark lynas

Central also is the misanthropic idea that there is a 'Nature' that exists in a state of perfected harmony and that humans and all their works are corrupting it. If only these twits realized that all of their beloved vegetables and most farm animals are hideous mutants.

Owen Paterson MP 🥝 @OwenPaterson

All too predictable ruling from the European Court which sadly "threatens research on gene-edited crops in the bloc", & will see investment move elsewhere as the EU condemns itself to become the Museum of World Farming nature.com/articles/d4158...





Follow

Hey EU! Politicians have decided you won't get gene edited crops. Fire up the Cesium 137 source and order some ethyl methanesulfonate - you're doing it old school. Condolences to EU colleagues & farmers that can't benefit from the best technology.

European court plumbs the depths of scientific absurdity with today's gene editing

decision - random mutagenesis is OK, while

doctors can use blunderbuss but not scalpel.

precision editing is a 'GMO' and therefore

borderline illegal. Go figure! Like saying





- Cutting edge of CRISPR/genome editing
- Research, commentary and analysis
- Intended for (and edited by) the global CRISPR community
- Speed of peer review and production
- Print (6x/year), online and OA options
- **R**eleased February 2018

www.liebertpub.com/CRISPR

Mary Ann Liebert, Inc. 🏷 publishers



Editor-in-Chief





Executive Editor



Associate Editors



Sanley Lei Qi Stanford University





Samuel Sternberg Columbia University (

Managing Editor







(Germany)

Denis Bauer

San Francisco

CSIRO (Australia)

Joseph Bondy-Denomy

Emmanuelle Charpentier

Max Planck Institute

for Infection Biology

University of California,

George Church Harvard Medical School



Jennifer Doudna HHMI/University of California



Berkeley

Peter C. Fineran University of Otago (New Zealand)



Stephen Floor University of California, San Francisco

Duke University

Luke A. Gilbert

San Francisco

Patrick Hsu

Maria Jasin

Cancer Center

Salk Institute for

Biological Studies (USA)

Asma Hatoum-Aslan

University of Alabama



EDITORIAL BOARD



Dana Farber Cancer Institute (USA)

Anita Marchfelder

Ulm University (Germany)

Florida State University

Hong Li

University of California,



Karen Maxwell University of Toronto

Shondra Miller

(Spain)

Tony Nolan

St Jude's Children's **Research Hospital**





New York Law School

Massachusetts Medical

Chinese Academy of



Huimin Zhao University of Illinois

(Japan)





Matthew Porteus Stanford University

Hospital

Vikram Pattanayak

Massachusetts General



Malcolm White University of St Andrews (UK)

University of Exeter (UK)



Blake Wiedenheft Montana State University

Edze Westra



Matthew Willmann

Takashi Yamamoto

Hiroshima University

















School

Yanli Wang

Sciences



(Germany)



Iowa State University

Jacob Sherkow



Jian-Kang Zhu Shanghai Institute for **Biological Sciences**



Memorial Sloan Kettering

Eugene V. Koonin National Center for Biotechnology Information, NIH






Eric Olson University of Texas Southwestern

Imperial College, London



CRISPR on the Rise

CRISPR PAPERS



The Story So Far...



